期刊
ALLERGY AND ASTHMA PROCEEDINGS
卷 29, 期 5, 页码 530-537出版社
OCEAN SIDE PUBLICATIONS INC
DOI: 10.2500/aap.2008.29.3160
关键词
Anti-IgE; asthma; atopic dermatitis; biologic therapeutic; IgE; investigator global assessment; omalizumab; prospective; treatment
类别
Omalizumab is a unique biologic therapeutic drug approved for treating atopic patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. This study was performed to examine the efficacy of omalizumab for the treatment of atopic dermatitis (AD), a disease with siginificant morbidity. A prospective analysis was performed to assess the efficacy of omalizumab in 21 patients with moderate to severe persistent allergic asthma and AD. Patients were stratified into the following groups: very high IgE (> 700 IU/mL), high IgE (186-700 IU/mL), and normal IgE (0-185 IU/mL). AD severity was assessed at 0, 1, 3, 6, and 9 months via 0)7 Investigator Global Assessment index. Twenty-one patients (14-64 years old) were evaluated. Pretreatment IgE levels ranged from 18.2 to 8396 IU/mL, (mean IgE level was 1521. IU/mL). All 21 patients showed clinical and statistically significant improvement of their atopic dermatitis (p < 0.00052). In conclusion, this study indicates that omnalizumab is effective in treating AD in patients with moderate to severe persistent allergic asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据